Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in SMARCB1-Deficient Renal Medullary Carcinoma
NCT07438626Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in renal medullary carcinoma (RMC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
renal medullary carcinoma (RMC)
Beyond the preview
Go deeper on NCT07438626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438626.